Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial)
暂无分享,去创建一个
W. Gregory | J. Cavenagh | E. Low | G. Cook | K. Yong | L. Flanagan | Sarah R Brown | R. Popat | M. Streetly | H. Oakervee | B. Kishore | A. Hall